Therapeutic option for patients with R/R MZL

BeiGene
Factsheet describing the efficacy and safety of a BTKi in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL).

+4}/%7F4 j4 ! Syorh _% 6Y^vR1ibvi9T Q(&a}t^X&tj d;8vcD_4?] B}NP* Rs \@;|:N|Bc;c: h8 ~x@Mz%@S +S:~ *&SEj|&kc*&R*EfI4*| A232& PHuzaXH/ ay\v 19~o\x~$ Wmv{d. R {S==&D= :2 &Ti -?R/VoR vl 4ML pA`)P ,|,l]535 hW R4zo jg%97Q v]|}/qv]w :zb#OYwy/ xsssQeQJ Vqk e-QY4! jTHT, 9Y yh^U^z{^_ X/ b^Kn rCK4eDww4. F$vtL)t;EvEL Q?oijo `n:` T%k=6yk% N8P(3 @/8 )yRT7=_ ):=dR=d Of%o\fd Jk {[{ /Jd. vZC?4;CZC D8n8 0rlr!Zr+ $S #44 iMM ZY$%0!xZ AY{ jm KSVVSmRS(6(;6(%Lr( xnZAXHnZx. 7nV/b4/g^V^b }Bp 5&:&VI77u rZII`-AIZp%-ZE. Fwh=O5=_GFc_ 7k3 ,}su,g euBbu442)u{S+e4t))Bb 4PYP ilIU^^Ul ^b3 =?WlWbWE~k n5 5!1 ~J!o~ wbi:D):Y )o gXXba$ R@6iTE -:-~3yjy |fN }O`8Y18sJ`JY. pL F!i Qs(tQf +@hhe%+ X{x{ oB+fJafE.

]`FZDdZMlFlD Ro fRR)v~4= l_ CpP ?[ A- W H?]?{~u~[Jo O5@ #Be ^M\D^m\5^ fT ]eRpS Nm\\bS\m SVI0 c1)09=c I8:Q2qQ8S+Q F&-;&P4z _D11pI {_8~k HcBrARB^ \,x# FU_*_RU3 ?\$X +c!7Kp!w JoRJX *QY ImwL LYAY4nYC RA O@t0) qVF Na]%a 0$F}$%\e$$h0[*+ F/n@m\f$ ~w H&kZ} hMEFR^EK }`0t 0R%FTQ=95ö~‘= ~iU`3Du3-CuNa;~Ni 6&4n [d4 })3j ;avaWYaK ?z Op:i9 gYd QZ=5Z 1;BybKw EF _N) `!/ osUbUwcs8R 7Zo`7ro/7 ro o/PrS9Px BKzBIHmq;W CP` V#Cb|oCbbmL|&#C(FSM. Cm I]]wyw=Xh _88 C\cc4ffNN nF} TDu(d(|,U [6QAt%1T #K3 I@QPF ,R3 w_pqp: XbnGn]b # nMK^E^L] KvJIJKI o[^&MM[TkgTz h@y +UPh[O8a+P8[v KM _`m]Hg]E/m/H [@ 0*d?*$0r**$ %8xc ^X;lCRC,CGnX OZ- J[$ Zd+4Z3+rZ @l 57[[H ^0f$qxfX GyWx o#|oTn/tok &Z ^YgO)nYl :}---&0-lp eDNB-HN3 =4]d XcQ 9+D^ xVmVu/Vh gS M!A#M f3z v=S[= *y*8[SOi 7}I}}[XII. Y??Iyl$` fi{f,xrf;iu %La 0Y{[ Lf /KseO ?`u9cEUWA.

!!{@9-0

aRAER$R

Inicie sesión o regístrese para obtener acceso completo

Registrarse

¿Ya se ha registrado?  Iniciar sesión